Verve Therapeutics Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Verve Therapeutics Inc in the first quarter 2025?
Verve Therapeutics Inc recorded a cumulative net loss of $-181 million during 12 months ending in the first quarter 2025, resulting in a negative return on equity (ROE) of -35.82%.

Within the Major Pharmaceutical Preparations industry 145 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the fourth quarter 2024 from 2465 to 3217.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter	(Jun 30 2024) II. Quarter	(Mar 31 2024) I. Quarter
Y / Y Equity Change	-18.79 %	-17.7 %	10.47 %	17.38 %	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in Millions	-181	-199	-197	-193	-197
Return On Equity (TTM)	-35.82 %	-37.3 %	-35.23 %	-35.2 %	-37.35 %
VERV's Total Ranking	# 3217	# 2465	# 2834	# 2837	# 0
Equity (TTM) in Millions	474	493	509	546	583
Seq. Equity Change	-4.03 %	-2.98 %	-6.87 %	-6.34 %	-2.74 %
Seq. Net Income Change	-	-	-	-	-

Back to VERV Management Effectiveness >> VERV's 5 Years Annual ROE >> Compare VERV ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 146
Sector	# 367
Overall	# 3217

Return On Equity Statistics
High	Average	Low
-35.2 %	-37.63 %	-44.41 %
(Jun 30 2024)		(Dec 31 2021)

News about Verve Therapeutics Inc Return on Equity ROE

Navigating Market Turbulence with Scientific Tenacity Verve Therapeutics and the Quest for Heart Health Breakthroughs...

Gene Editing’s Next Leap: Verve Therapeutics Charts New Territory with Promising Pipeline In the fast-evolving landscape of biotechnology, Verve Therapeutics is charting a bold course toward the future of precision medicine, despite a challenging performance on the stock market. With a focus on pioneering treatments through gene editing, Verve is steering its efforts towards an ambitious goal: reducing the burden of cardiovascular diseases by permanently switching off genes that cause high cholesterol. At the heart of these endeavors is the company’s latest progress report, which places significant emphasis on its promising pipeline and anticipated milestones for 2025.Central to Verve’s advancements is the Heart-2 Phase 1b clinical trial of VERVE-102, their novel treatment targeting the PCSK9 gene. PCSK9 is integral to cholesterol regulation, and its inhibition could potentially revolutionize the management of heart disease, offering a one-time treatment solution instead of lifelong medication adherence. Verve aims to have initial data for this critical trial available by the second quarter of 2025, a timeline eagerly watched by both investors and the scientific community.

VERV Annual Return On Equity	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	493	600	551	357	0
Y / Y Equity Change	-17.7 %	8.82 %	54.17 %	-	-
Net Income in Millions	-199	-200	-157	-120	0
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	-40.27 %	-33.37 %	-28.57 %	-33.67 %	-

Back to VERV Management Effectiveness >> VERV's 5 Years Annual ROE >> Compare VERV ROE to its Competitors

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
VERV's' Return on Equity at Yahoo Finance
VERV's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for VERV's Competitors
Subscribers only: Roe for Verve Therapeutics Inc 's Suppliers
Subscribers only: Return On Equity for VERV's Customers

Companies with similar Return On Equity at Mar 31 2025, within Healthcare Sector

ROE

Date modified: 2026-09-18T13:11:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.